查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048173

生物PCR技術市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用途、地區和競爭格局分類，2021-2031年

Biological PCR Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物PCR技術市場預計將從2025年的135.1億美元大幅成長至2031年的207.6億美元，複合年成長率為7.42%。

生物PCR技術是一種基本的分子診斷技術，用於擴增特定的DNA片段，從而在臨床、調查和法醫學領域實現對遺傳物質的準確檢測和分析。

市場概覽
預測期 2027-2031
市場規模：2025年 135.1億美元
市場規模：2031年 207.6億美元
複合年成長率：2026-2031年 7.42%
成長最快的細分市場 試劑
最大的市場 北美洲

市場擴張的主要驅動力是感染疾病發病率的上升以及腫瘤學和個人化醫療領域對基因檢測需求的成長。例如，全球整體（世衛組織）報告稱，2024年新增結核病病例達830萬例，凸顯了精準分子診斷的迫切需求。然而，先進PCR設備的高昂成本以及對專業技術人員的必要要求限制了市場成長。這些因素構成了重大的財務和營運障礙，尤其限制了資源匱乏的發展中地區的應用。

市場促進因素

即時檢測 (POC) 和攜帶式診斷設備的日益普及正對該市場產生顯著影響。這些設備推動了分子診斷的去中心化，並使人們能夠在傳統實驗室之外快速做出決策。這項變革的驅動力在於將複雜的 PCR 流程整合到緊湊、易用的平台中的創新技術，從而大幅縮短了報告檢測結果所需的時間，而這些結果對於感染疾病控制至關重要。生物梅里埃 (bioMerieux) 的 BIOFIRE SPOTFIRE R/ST Panel Mini 就是一個典型的例子，該產品於 2024 年 6 月獲得了 FDA 和 CLIA 的豁免核准。這是一款多重 PCR 檢測產品，可在約 15 分鐘內檢測五種常見病原體，直接滿足分散式緊急醫療需求。

同時，受全球傳染病負擔日益加重的推動，感染疾病管理領域臨床應用不斷擴展，顯著加速了市場成長。隨著病原體爆發的增加，醫療衛生系統正優先採用高靈敏度的分子診斷技術進行早期檢測和標靶治療。世界衛生組織（世衛組織）2024年12月發布的報告估計，2023年全球瘧疾病例將達到2.63億例（比前一年增加約1,100萬例），凸顯了加強診斷監測的迫切性。因此，主要行業參與者正在擴大營運規模並取得顯著的商業性成功。例如，羅氏診斷部門報告稱，2024年銷售額將達到143億瑞士法郎，其核心業務成長8%，這主要得益於市場對免疫診斷和分子診斷解決方案的強勁需求。

市場挑戰

全球生物PCR技術市場的發展受到高昂成本的嚴重限制，這些成本包括購買先進設備所需的高昂費用以及必要的專業技術知識。這些財務和營運障礙嚴重限制了複雜PCR系統的應用，尤其是在資源匱乏的環境和開發中國家。對於預算有限的檢查室，證明對先進擴增平台進行初始投資的合理性往往十分困難，而持續的維護和試劑成本進一步加劇了財務壓力。這些經濟限制因素限制了市場滲透率，並阻礙了分子診斷技術在感染疾病防治關鍵領域的廣泛應用。

除了上述經濟負擔外，更嚴格的報銷條件也減少了檢查室可用於投資這些昂貴技術的資金。例如，根據美國臨床實驗室協會 (ACLA) 的報告，預計到 2024 年，聯邦醫療保險 (Medicare) 對臨床檢查室約 800 項診斷測試的報銷額將減少高達 15%。營運收入的下降直接削弱了醫療機構投資昂貴的 PCR 系統和聘用操作這些系統所需熟練人員的能力，從而阻礙了市場的整體成長潛力。

市場趨勢

該市場的主要驅動力是PCR技術在液態生物檢體和腫瘤學領域應用的不斷擴展，尤其是在微量殘存疾病（MRD）監測和非侵入性癌症檢測方面。這一趨勢標誌著檢測方式從侵入性組織切片檢查轉向血液檢測，從而能夠準確識別循環腫瘤DNA（ctDNA），並有助於預測癌症復發。 PCR整合工作流程日益受到臨床認可，腫瘤檢測服務量大幅成長，進而推動了對高靈敏度擴增技術的需求。例如，Natera公司2025年11月發布的報告顯示，該公司在2025年第三季進行了約21.1萬例腫瘤檢測，年增53.9%，凸顯了這些分子診斷解決方案的快速普及。

此外，PCR檢測技術在食品安全和農業領域的拓展，使其效用超越了傳統的臨床醫學。工業實驗室正加速採用快速分子檢測方法取代傳統的培養方法，以確保供應鏈的完整性，並符合病原體檢測的嚴格監管標準。這種向工業應用的轉變，催生了對專用試劑和自動化平台的強勁需求，這些試劑和平台旨在為高通量環境提供更快速的檢測結果。例如，根據生物梅里埃公司截至2025年3月的會計年度財務報告，其工業應用部門全年銷售額成長約9%，主要得益於食品安全領域試劑銷售額的兩位數成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：生物PCR技術的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（試劑、耗材）
    • 依應用領域（診斷檢查室、分子檢查室）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物PCR技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物PCR技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物PCR技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物PCR技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物PCR技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物PCR技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories Inc.
  • QIAGEN GmbH
  • Takara Bio Inc.
  • Merck KGaA
  • Bioneer Corporation
  • Illumina, Inc.
  • Promega Corporation
  • Eppendorf SE

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27625

The Global Biological PCR Technology Market is projected to expand significantly, rising from USD 13.51 Billion in 2025 to USD 20.76 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.42%. At its core, biological PCR technology serves as a fundamental molecular diagnostic technique for amplifying specific DNA segments, enabling the precise detection and analysis of genetic material across clinical, research, and forensic applications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 13.51 Billion
Market Size 2031USD 20.76 Billion
CAGR 2026-20317.42%
Fastest Growing SegmentReagents
Largest MarketNorth America

This market expansion is largely fueled by the escalating incidence of infectious diseases and the growing need for genetic testing within oncology and personalized medicine, as exemplified by the 8.3 million new tuberculosis diagnoses reported globally in 2024 by the World Health Organization, highlighting the urgent demand for accurate molecular diagnostics. Nevertheless, the market's growth is constrained by the considerable costs linked to advanced PCR instrumentation and the imperative for specialized technical expertise, which present significant financial and operational hurdles, particularly limiting adoption in resource-constrained developing regions.

Market Driver

The market is profoundly influenced by the growing adoption of point-of-care (POC) testing and portable diagnostic devices, which are decentralizing molecular diagnostics and facilitating swift decision-making beyond conventional laboratory environments. This evolution is driven by innovations integrating intricate PCR processes into compact, user-friendly platforms, thereby substantially shortening turnaround times crucial for managing infectious diseases. An illustrative instance is bioMerieux's June 2024 FDA and CLIA-waiver approval for its BIOFIRE SPOTFIRE R/ST Panel Mini, a multiplex PCR test detecting five common pathogens in about 15 minutes, directly supporting decentralized urgent care needs.

Concurrently, the expansion of clinical applications for infectious disease management is a significant market accelerator, propelled by the rising global burden of such conditions. As pathogen prevalence increases, healthcare systems are prioritizing highly sensitive molecular techniques for early detection and targeted treatments. The World Health Organization's December 2024 report, noting an estimated 263 million malaria cases globally in 2023-an increase of approximately 11 million from the previous year-underscores the urgent demand for robust diagnostic surveillance. Consequently, leading industry players are scaling operations and achieving substantial commercial success, as evidenced by Roche's Diagnostics Division reporting CHF 14.3 billion in sales for 2024, with its base business growing 8% due to high demand for immunodiagnostic and molecular solutions.

Market Challenge

The Global Biological PCR Technology Market is significantly impeded by the substantial implementation costs of advanced instrumentation and the essential requirement for specialized technical expertise. These financial and operational obstacles severely limit the adoption of complex PCR systems, especially within resource-constrained environments and developing economies. Laboratories with limited budgets often find it challenging to justify the initial capital outlay for sophisticated amplification platforms, and the recurring expenditures for maintenance and reagents further exacerbate financial pressures. This economic constraint restricts the market's reach, hindering the broad deployment of molecular diagnostic capabilities in areas where they are often most crucial for managing infectious diseases.

Adding to this financial burden is a tightening reimbursement landscape, which reduces the capital available for laboratories to invest in these expensive technologies. For instance, in 2024, clinical laboratories encountered scheduled Medicare reimbursement cuts of up to 15% for roughly 800 diagnostic tests, as reported by the American Clinical Laboratory Association. Such reductions in operational revenue directly diminish healthcare facilities' capacity to acquire costly PCR systems and employ the necessary skilled personnel to operate them, consequently inhibiting the market's overall growth potential.

Market Trends

The market is significantly advanced by the increasing application of PCR in liquid biopsy and oncology, particularly for monitoring Minimal Residual Disease (MRD) and non-invasive cancer detection. This trend marks a shift from invasive tissue biopsies to blood-based testing, facilitating the accurate identification of circulating tumor DNA (ctDNA) to predict cancer recurrence. The growing clinical acceptance of these PCR-integrated workflows is demonstrated by the substantial rise in oncology testing services, which in turn boosts demand for high-sensitivity amplification technologies. Natera's November 2025 report, for instance, indicated the company performed approximately 211,000 oncology tests in the third quarter of 2025, a 53.9% increase year-over-year, highlighting the rapid adoption of these molecular solutions.

Furthermore, the expansion of PCR testing into the food safety and agricultural sectors is extending the technology's utility beyond traditional clinical healthcare. Industrial laboratories are increasingly adopting rapid molecular assays over conventional culture-based methods to ensure supply chain integrity and adhere to strict regulatory standards for pathogen detection. This move towards industrial applications is generating strong demand for specialized reagents and automated platforms engineered to provide quicker results in high-throughput environments. BioMerieux's March 2025 financial report, for example, showed its Industrial Applications division achieved nearly 9% sales growth for the full year, largely propelled by double-digit increases in reagent sales within the food safety segment.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories Inc.
  • QIAGEN GmbH
  • Takara Bio Inc.
  • Merck KGaA
  • Bioneer Corporation
  • Illumina, Inc.
  • Promega Corporation
  • Eppendorf SE

Report Scope

In this report, the Global Biological PCR Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biological PCR Technology Market, By Product Type

  • Reagents
  • Consumables

Biological PCR Technology Market, By End Use

  • Diagnostic Laboratories
  • Molecular Testing Laboratories

Biological PCR Technology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biological PCR Technology Market.

Available Customizations:

Global Biological PCR Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biological PCR Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Reagents, Consumables)
    • 5.2.2. By End Use (Diagnostic Laboratories, Molecular Testing Laboratories)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Biological PCR Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biological PCR Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Biological PCR Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Biological PCR Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End Use

7. Europe Biological PCR Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biological PCR Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Biological PCR Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Biological PCR Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Biological PCR Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Biological PCR Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End Use

8. Asia Pacific Biological PCR Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biological PCR Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Biological PCR Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Biological PCR Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Biological PCR Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Biological PCR Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Biological PCR Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biological PCR Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Biological PCR Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Biological PCR Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End Use

10. South America Biological PCR Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biological PCR Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Biological PCR Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Biological PCR Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biological PCR Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Bio-Rad Laboratories Inc.
  • 15.4. QIAGEN GmbH
  • 15.5. Takara Bio Inc.
  • 15.6. Merck KGaA
  • 15.7. Bioneer Corporation
  • 15.8. Illumina, Inc.
  • 15.9. Promega Corporation
  • 15.10. Eppendorf SE

16. Strategic Recommendations

17. About Us & Disclaimer